Medical Professionals Reference (MPR)Elunetirom Gets Fast Track Designation for Bipolar Depression

📋 Regulatory Action / Label Change

The FDA has designated elunetirom, an oral CNS thyroid hormone receptor agonist, for Fast Track review in adjunctive bipolar I and II depression. The designation accelerates regulatory dialogue but reflects unmet need, not demonstrated clinical efficacy; all supporting data remain preclinical.

Professional Impact

• Elunetirom targets neurogenesis, synaptogenesis, and mitochondrial biogenesis via CNS thyroid hormone receptor agonism, which is a mechanistic approach distinct from existing mood stabilizers and second-generation antipsychotics
• The ongoing AMPLIFY-BD phase 2 trial (NCT06869187) will enroll approximately 30 adults on background mood stabilizers or atypical antipsychotics; primary endpoint is HAMD-17 change at week 6
• Topline data from AMPLIFY-BD are expected Q2 2026; a parallel MDD trial (AMPLIFY, NCT06633016) targets Q3 2026 readout
• Fast Track designation expedites FDA review meetings and rolling submission but does not signal efficacy or accelerate approval timelines absent clinical data

Action Items

• Monitor AMPLIFY-BD topline results expected imminently for first human efficacy signal
• Note the adjunctive-only design: elunetirom is studied on top of mood stabilizers or atypical antipsychotics, not as monotherapy
• Contextualize Fast Track for patients who may interpret designation as near-term availability; phase 2 enrollment of 30 patients reflects early-stage development
• Track the MDD pipeline in parallel: AMPLIFY results will inform whether the mechanism extends beyond bipolar depression